The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis

Current Opinion in Obstetrics and Gynecology

Volumn 25, Issue 4, 2013, Pages 287-292

  Divasta, Amy D ^a   Laufer, Marc R ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

add back therapy; adolescents; endometriosis; gonadotropin releasing hormone agonist

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BUSERELIN; ESTROGEN; ESTROGEN RECEPTOR; FOLLITROPIN; GESTAGEN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADOTROPIN; GOSERELIN; HISTRELIN; LETROZOLE; LEUPRORELIN; LEVONORGESTREL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NAFARELIN; NORETHISTERONE ACETATE; STEROID HORMONE; TAMOXIFEN;

ADOLESCENT; BODY WEIGHT; BONE DENSITY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIOSIS; ESTROGEN BLOOD LEVEL; FATIGUE; FOLLITROPIN BLOOD LEVEL; HAIR LOSS; HOT FLUSH; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIBIDO DISORDER; LONG TERM CARE; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; MOOD CHANGE; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA BLEEDING; VAGINA PAIN; VAGINAL DRYNESS;

ADOLESCENT; BONE DENSITY; CLINICAL TRIALS AS TOPIC; ENDOMETRIOSIS; FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFLAMMATION; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84880814757     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32836343eb     Document Type: Review

References (41)

1. ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents. Obstet Gynecol 2005; 105:921-927.
2. Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10:199-202.
3. Kanis JA. Assessment of fracture risk: who should be screened? In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th ed. Washington, D.C: American Society for Bone and Mineral Research; 2003. pp. 316-323.
4. Kettel LM, Hummel WP. Modern medical management of endometriosis. Obstet Gynecol Clin North Am 1997; 24:361-373.
5. Meresman GF, Bilotas M, Buquet RA, et al. Gonadotropin-releasing hormone agonist induces apoptosis and reduces cell proliferation in eutopic endometrial cultures from women with endometriosis. Fertil Steril 2003; 80 (Suppl 2): 702-707.
6. Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010; 25:642-653.
7. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; CD008475.
8. Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85:314-325.
9. Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20:1993-1998.
10. Guzick DS, Huang LS, Broadman BA, et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosisassociated pelvic pain. Fertil Steril 2011; 95:1568-1573.
11. Miller JD. Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. Am J Obstet Gynecol 2000; 182:1483-1488.
12. Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol 2011; 9:89.
13. Warnock JK, Bundren JC, Morris DW. Depressive mood symptoms associated with ovarian suppression. Fertil Steril 2000; 74:984-986.
14. Zhao L, Wu H, Zhou X, et al. Effects of progressive muscular relaxation training on anxiety, depression and quality of life of endometriosis patients under gonadotrophin-releasing hormone agonist therapy. Eur J Obstet Gynecol Reprod Biol 2012; 162:211-215.
15. Ferreira RA, Vieira CS, Rosa ESJC, et al. Effects of the levonorgestrelreleasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception 2010; 81:117-122.
16. Cagnacci A, Tirelli A, Cannoletta M, et al. Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis. Contraception 2005; 72:443-446.
17. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91:16-24.
18. Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropinreleasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992; 75:558-563.
19. Matsuo H. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis. Fertil Steril 2004; 81:149-153.
20. Al-Azemi M, Jones G, Sirkeci F, et al. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain. BJOG 2009; 116:1646-1656.
21. Revilla R, Revilla M, Hernandez ER, et al. Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered. Maturitas 1995; 22:145-150.
22. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99:709-719.
23. Pierce SJ, Gazvani MR, Farquharson RG. Long-term use of gonadotropinreleasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril 2000; 74:964-968.
24. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752-e762.
25. Miller BS, Shukla AR. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists. Clin Therap 2010; 32:1749-1751.
26. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166:740-745.
27. Cedars MI, Lu JK, Meldrum DR, Judd HL. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 1990; 75:641-645.
28. Surrey ES, Gambone JC, Lu JK, Judd HL. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 1990; 53:620-626.
29. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990; 70:920-924.
30. Surrey ES, Fournet N, Voigt B, Judd HL. Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a longacting GnRH agonist: a preliminary report. Obstet Gynecol 1993; 81:581-586.
31. Kiilholma P, Tuimala R, Kivinen S, et al. Comparison of the gonadotropinreleasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril 1995; 64:903-908.
32. Finkelstein JS, Klibanski A, Schaefer EH, et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994; 331:1618-1623.
33. Kiesel L, Schweppe KW, Sillem M, Siebzehnrubl E. Should add-back therapy for endometriosis be deferred for optimal results? Br J Obstet Gynaecol 1996; 103 (Suppl 14):15-17.
34. Hurst BS, Gardner SC, Tucker KE, et al. Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. JSLS 2000; 4:97-101.
35. Franke HR, van de Weijer PH, Pennings TM, van der Mooren MJ. Gonadotropin- releasing hormone agonist plus 'add-back' hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo- controlled, double-blind trial. Fertil Steril 2000; 74:534-539.
36. Fuldeore MJ, Marx SE, Chwalisz K, et al. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin 2010; 26:729-736.
37. Divasta AD, Laufer MR, Gordon CM. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. J Pediatr Adolesc Gynecol 2007; 20:293-297.
38. ACOG Practice Bulletin No. Medical management of endometriosis. Obstet Gynecol 1999; 94:1-14.
39. Bedaiwy MA, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril 2006; 86:220-222.
40. Miller JD, Shaw RW, Casper RF, et al. Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotropin-releasing hormone agonist. Fertil Steril 1998; 70:293-296.
41. Kitawaki J, Ishihara H, Kiyomizu M, Honjo H. Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosisassociated pelvic pain. Fertil Steril 2008; 89:1831-1835.